Infertility
Conditions
Keywords
infertility, ovulation dysfunction, endometrium, tamoxifen, clomiphene citrate
Brief summary
About 10-15% of all couples attempting to conceive will not become pregnant within one year. Among those, the majority will have ovulatory dysfunction, mild male infertility or unexplained infertility. The traditional first line therapy for those couples is ovulation induction or superovulation using clomiphene citrate. Probably due to anti-estrogenic effects of this agent will, some patients will have a thin endometrium as measured by sonography at the time of ovulation. This phenomenon may be associated with a lower chance to conceive. Tamoxifen is a similar molecule that has been used to clomiphene citrate that has been shown to be equally effective to clomiphene in ovulation induction. Preliminary observations showed that tamoxifen does not cause a negative effect on the endometrium as compared with clomiphene, and may increase the chance to conceive in those patients who have a thin endometrium under clomiphene.
Interventions
DRUGtamoxifen
DRUGclomiphene citrate
Sponsors
Shaare Zedek Medical Center
Study design
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 35 Years
Healthy volunteers
No
Inclusion criteria
* Primary or secondary infertility due to: * Ovulatory dysfunction * Mild male infertility * Unexplained infertility * Endometrium \< 6 mm at time of hCG during previous treatment with clomiphene citrate * Age 18-35
Exclusion criteria
* Serious adverse effects under clomiphene citrate or known sensitivity to either tamoxifen or clomiphene citrate
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pregnancy rate | — |
| delivery rate | — |
Secondary
| Measure | Time frame |
|---|---|
| endometrium thickness | — |
| percentage of ovulation | — |
| number of follicles | — |
Countries
Israel
Contacts
Primary ContactAvi Tsafrir, MD
Outcome results
None listed